DrugPatentWatch Database Preview
Details for Patent: 8,062,665
Which drugs does patent 8,062,665 protect, and when does it expire?
Patent 8,062,665 protects PROMACTA and is included in one NDA.
Protection for PROMACTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-seven patent family members in thirty-two countries.
Summary for Patent: 8,062,665
| Title: | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1- '-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| Abstract: | Disclosed are novel pharmaceutical compositions containing 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. |
| Inventor(s): | Muller; Francis X (King of Prussia, PA), Kapsi; Shivakumar G (King of Prussia, PA) |
| Assignee: | GlaxoSmithKline LLC (Philadelphia, PA) |
| Application Number: | 12/607,320 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Process; Use; |
Drugs Protected by US Patent 8,062,665
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-001 | Nov 20, 2008 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-002 | Nov 20, 2008 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-003 | Sep 8, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,062,665
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 059656 | Start Trial | |||
| Argentina | 107711 | Start Trial | |||
| Australia | 2007352608 | Start Trial | |||
| Brazil | PI0721651 | Start Trial | |||
| Canada | 2685831 | Start Trial | |||
| Chile | 2007002242 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
